| A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome (NCT07727486) | Beijing InnoCare Pharma Tech Co., Ltd. | 2026-08-01 |
| Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study (NCT07440537) | Beijing InnoCare Pharma Tech Co., Ltd. | 2026-04-27 |
| Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects (NCT07535099) | Beijing InnoCare Pharma Tech Co., Ltd. | 2026-03-13 |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria (NCT07378527) | Beijing InnoCare Pharma Tech Co., Ltd. | 2026-02-13 |
| Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis (NCT07251998) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-12-22 |
| Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis (NCT07236099) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-11-27 |
| A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) (NCT07082686) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-08-21 |
| Evaluation of ICP-B794 in Patients With Advanced Solid Tumors (NCT07136558) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-08-01 |
| ICP-332 in Subjects With Non-segmental Vitiligo (NCT07047612) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-05-09 |
| Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis (NCT06842199) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-03-20 |
| Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT06845241) | Beijing InnoCare Pharma Tech Co., Ltd. | 2025-02-01 |
| ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis (NCT06775860) | Beijing InnoCare Pharma Tech Co., Ltd. | 2024-11-14 |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) (NCT06378138) | Beijing InnoCare Pharma Tech Co., Ltd. | 2024-05-15 |
| Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06521255) | Beijing InnoCare Pharma Tech Co., Ltd. | 2024-05-07 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis (NCT06109818) | Beijing InnoCare Pharma Tech Co., Ltd. | 2024-01-04 |
| Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma (NCT06082102) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-12-19 |
| Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia (NCT06004856) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-10-26 |
| Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT05719701) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-03-29 |
| Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis (NCT05702268) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-03-18 |
| Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject (NCT05684653) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-03-17 |
| The Study of ICP-248 in Patients With Mature B-cell Malignancies (NCT05728658) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-03-09 |
| Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies (NCT05690581) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-02-23 |
| Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors (NCT05745623) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-12-27 |
| Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects (NCT05660720) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-11-19 |
| A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma (NCT05678270) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-11-15 |
| A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (NCT05234684) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-11-02 |
| A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis (NCT05451199) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-07-29 |
| A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors (NCT05370755) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-05-31 |
| A Study of ICP-033 in Patients With Advanced Solid Tumors (NCT05367232) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-02-25 |
| A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia (NCT05232149) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-02-21 |
| DDI Study of Orelabrutinib (NCT05316857) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-12-16 |
| A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations (NCT05372120) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-12-15 |
| A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT05210868) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-11-16 |
| Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL (NCT05552937) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-09-06 |
| A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects (NCT05399030) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-08-14 |
| A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis (NCT04711148) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-03-01 |
| A Study of ICP-192 in Patients With Advanced Solid Tumors (NCT04565275) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-02-01 |
| ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL (NCT04578613) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-01-08 |
| A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors (NCT04685226) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-09-27 |
| A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (NCT04304040) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-07-28 |
| A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) (NCT04305197) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-07-09 |
| An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer (NCT04492293) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-05-27 |
| A Study of ICP-022 in Patients With R/R DLBCL (NCT04438005) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-05-07 |
| A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies (NCT04014205) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-11-18 |
| A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (NCT04440059) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-08-10 |
| ADME Study of [14C]ICP-022 in Healthy Males (NCT04441450) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-07-01 |
| A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL (NCT04438044) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-06-18 |
| A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) (NCT03797456) | Beijing InnoCare Pharma Tech Co., Ltd. | 2019-04-01 |
| Clinical Study of ICP-192 in Solid Tumors Patients (NCT03758664) | Beijing InnoCare Pharma Tech Co., Ltd. | 2018-12-19 |
| A Study to Evaluate ICP-022 in Patients With CLL/ SLL (NCT03493217) | Beijing InnoCare Pharma Tech Co., Ltd. | 2018-04-17 |
| A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (NCT03494179) | Beijing InnoCare Pharma Tech Co., Ltd. | 2018-04-02 |